Drugs / Bepirovirsen
Bepirovirsen
Trials 14 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07168356 | Sep 2025 → Mar 2026 overdue | hepatitis B virus infection | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06058390 | Oct 2023 → May 2024 | chronic hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT04971928 | Sep 2021 → May 2022 | hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05330455 | Apr 2022 → May 2025 | chronic hepatitis B virus infection | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 28 trials | ||||||
| Phase 2 | NCT07696520 | Jul 2026 → Dec 2027 expected | chronic hepatitis B virus infection | National University Health System, Singapore | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06537414 | Nov 2024 → May 2027 expected | chronic hepatitis B virus infection | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06497504 | Sep 2024 → Apr 2027 expected | hepatitis B virus infection | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05276297 | Mar 2022 → Aug 2025 | chronic hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT04676724 | Jan 2021 → Feb 2023 | chronic hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT04544956 | Oct 2020 → Nov 2023 | hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT04449029 | Jul 2020 → Mar 2022 | chronic hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT02981602 | Feb 2017 → Dec 2019 | chronic hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05630807 | Dec 2022 → Nov 2025 | chronic hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT05630820 | Dec 2022 → Nov 2025 | chronic hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06422767 Comparator | Jul 2024 → Apr 2025 | hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04954859 Background | Dec 2021 → Jan 2029 expected | hepatitis B virus infection | GlaxoSmithKline | Active not recruiting | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bepirovirsen | “Bepirovirsen (GSK3228836) is an antisense oligonucleotide that induced rapid and prolonged hepatitis B surface antigen (HBsAg) reduction with a favorable safety profile...” PMID 37393402 ↗ Jul 202311“Bepirovirsen is an antisense oligonucleotide currently in Phase 3 development to treat chronic hepatitis B virus (HBV) infection.” PMID 39950613 ↗ Feb 2025 |
| Known as | GSK-3228836B | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650468 ↗ |
| Known as | GSK3228836 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04676724 ↗ |
| Known as | IONIS HBVRX | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650468 ↗ |
| Known as | ISIS 505358 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650468 ↗ |
| Known as | ISIS-GSK3RX | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650468 ↗ |
| Action | Inhibit | “bepirovirsen leads to reductions in HBV-derived RNAs” PMID 34642494 ↗ Oct 2021 |
| Modality | Antisense oligonucleotide | “Bepirovirsen is an antisense oligonucleotide” PMID 39950613 ↗ Feb 2025 |
| Route | Subcutaneous | “administered subcutaneously” NCT02981602 ↗ |